drugset / Trial / NCT03720288

Acetazolamide in Patients With Acute Heart Failure

NCT03720288

Phase 3 Unknown 90 enrolled University of Sao Paulo General Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Introduction: Recent studies have suggested that the use of acetazolamide may assist in the vol- ume management of patients with decompensated heart failure (HF). However, prospective and randomized comparison in patients with HF and optimized diuretic therapy has not been described. Objective: The aim of this study was to evaluate the effectiveness and safety of the use of acetazolamide versus placebo in volume control in patients with decompensated HF. Methodology: For this, a unicentric, randomized, double blind and prospective study will be performed in a comparative manner. Hospital data (test results, medical outcomes, drug dose, complications) of patients will be analyzed for safety and effectiveness. Expected results: The use of acetazolamide as an adjuvant treatment is superior to the standard strategy for volume control in patients with decompensated HF.

Timeline

Start
2018-10-01
Primary completion
2019-10-01
Completion
2020-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Acetazolamide Small molecule 250 mg Oral

Indications